Onxeo has engaged MCT (Regional CRO specialized on Middle East and Africa) to expand “Relieve” phase III HCC study in 3 Middle East countries (Lebanon, Egypt and Saudi Arabia). More information in Onxeo press release: 150326EN_Livatag
Related Posts
Interview of Nada Taha, MCT Senior CRA/ TeamLead on Middle East Radio station
News / September 7, 2015
New office in Senegal
News / March 1, 2016